MedTrace Logo

Safety and PK Study of CC-90003 in Relapsed/Refractory Solid Tumors

NCT02313012 · Status: TERMINATED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 19

Last updated 2019-11-18

No results posted yet for this study

Summary

The CC-90003-ST -001 trial is a first-in-man, open-label study in subjects with locally-advanced or wide spread cancers to determine if CC-90003 (an oral medication) can be adequately tolerated with minimal side effects.

Conditions

  • Neoplasm Metastasis

Interventions

DRUG

CC-90003

CC-90003 PO once daily

Sponsors & Collaborators

  • Celgene

    lead INDUSTRY

Principal Investigators

  • Gordon Bray, MD · Celgene

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2015-01-05
Primary Completion
2016-05-03
Completion
2016-05-03

Countries

  • United States
  • Australia

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02313012 on ClinicalTrials.gov